SCHEMBL13699242

SCHEMBL13699242

CCC(CC)NC(=O)Nc1ccc(Oc2ccc(N(CCOC)C(=O)c3ccc(OC4CC5CCC(C4)N5)cc3)cc2)c(OC)c1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PKM P14618 1/20 0.37
MCHR1 Q99705 9/20 0.37
TAS1R3 Q7RTX0 1/20 0.37
TAS1R1 Q7RTX1 1/20 0.37
FGFR1 P11362 1/20 0.35
MAPT P10636 3/20 0.34
MEN1 O00255 3/20 0.34
KMT2A Q03164 3/20 0.34
GAA P10253 2/20 0.34
HTT P42858 2/20 0.34
NPC1 O15118 1/20 0.33
ALDH1A1 P00352 1/20 0.33
TP53 P04637 1/20 0.33
RAB9A P51151 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
CHRNB4 P30926 1/20 0.33
CHRNA3 P32297 1/20 0.33
POLB P06746 1/20 0.33
ABL1 P00519 1/20 0.33
RIN1 Q13671 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4235345 0.90 PKM (0.38) PKMMCHR1TAS1R3TAS1R1FGFR1
SCHEMBL4745445 0.87 MCHR1 (0.38) PKMMCHR1TAS1R3TAS1R1MAPT
SCHEMBL4232733 0.87 PKM (0.45) PKMMCHR1TAS1R3TAS1R1FGFR1
SCHEMBL4228512 0.85 SMN1; SMN2 (0.41) PKMMCHR1TAS1R3TAS1R1FGFR1
SCHEMBL4229108 0.85 MCHR1 (0.36) PKMMCHR1TAS1R3TAS1R1FGFR1
SCHEMBL13699331 0.84 CHRM1 (0.39) PKMMCHR1TAS1R3TAS1R1MAPT
SCHEMBL4237954 0.84 SMN1; SMN2 (0.39) PKMMCHR1TAS1R3TAS1R1FGFR1
SCHEMBL4233925 0.84 PKM (0.39) PKMMCHR1TAS1R3TAS1R1FGFR1
SCHEMBL13699221 0.83 CYP2D6 (0.40) PKMMCHR1TAS1R3TAS1R1MAPT
SCHEMBL4226836 0.82 SMN1; SMN2 (0.41) PKMMCHR1TAS1R3TAS1R1FGFR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090233910-A1 Npy antagonists, preparation and uses CEREP (FR) 2009-09-17 US disclosed
US-20090233910-A1 Npy antagonists, preparation and uses CEREP (FR) 2009-09-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090233910-A1 Npy antagonists, preparation and uses NPY1R, NPY5R, NPY2R PKM 1734/4885MCHR1 47/4885TAS1R3 1436/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.